In This Section      

Ciccarone Articles

Ciccarone Center Research



Landmark Articles

The clinical utility of C-reactive protein in cardiovascular disease.
By: Musunuru K, Blumenthal RS, Mora S.

This review discusses the literature on hsCRP in asymptomatic populations, analyzes it according to CVD and diabetes, and provides summary recommendations for the use of hsCRP in clinical practice. In this context, we highlight recent data from the landmark JUPITER trial, which demonstrated that hsCRP can be used to target high-risk patients who have typical LDL-C concentrations and no known vascular disease or diabetes and who would benefit from statin use. We also summarize evidence that among patients treated with statin therapy, achieving low hsCRP concentrations may be a clinically relevant therapeutic goal along with achieving very low LDL-C concentrations.

Relation of C-reactive protein to abdominal adiposity
By: Brooks GC, Blaha MJ, Blumenthal RS.
The association between high-sensitivity C-reactive protein (hsCRP) and abdominal adiposity persists when taking into account body mass index. Elevation of hsCRP might be reversible with weight loss and exercise. In conclusion, clinical measurements of abdominal adiposity readily provide data elucidating the systemic inflammatory state of patients and can help guide intensity of lifestyle modifications, thus leading to reduction of this inflammation.
Read on Pubmed
The numbers are in – statins for the primary prevention of cardiovascular disease in women.
By: Duvernoy CS, Blumenthal R.
This study indicates that statin therapy among middle-aged and older women with low LDL-C but above average hsCRP achieves better outcomes than those previously observed in primary prevention trials that were conducted with less potent statins in individuals with overt hyperlipidemia. Clearly, the evidence base for statin therapy in asymptomatic middle-aged and older women with other risk factors is now much more compelling, thanks to the work of Mora and colleagues. We await publication of the formal cost-effectiveness analyses from the landmark JUPITER data set, as well as data on the long-term safety of high-potency statin therapy. In the meantime, clinicians will undoubtedly use the data by Mora et al to prescribe statin therapy much earlier for women who meet the entry criteria of the JUPITER study, and this change will improve cardiovascular outcomes in women.
Read on Pubmed
Favorable cardiovascular risk factor profile is associated with reduced prevalence of coronary artery calcification and inflammation in asymptomatic nondiabetic white men.
By: Michos ED, Santos RD, Narla V, Pandey S, Meneghelo R, Carvalho JA, Budoff MJ, Blumenthal RS, Nasir K.
In age-adjusted analysis, each lower cardiovascular risk factor (CVRF) profile was associated with lower odds of prevalent coronary artery calcium and elevated white blood cell count. Our study supports the notion that a favorable cardiovascular disease (CVD) profile is associated with less underlying atherosclerosis and inflammation and further highlights the importance of primary prevention of CVRFs.
Read on Pubmed
Use of high senstitivity C-reactive protein for risk assessment.
By: Campbell CY, Musunuru K, Mora S, Blumenthal RS.